Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Padmanee Sharma

Showing results (201-210 of 216) with videos related to

Pageof 22
Sort By:
Cancer Discovery|December 2, 2025
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Cancer Discovery|May 13, 2026
A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune ArchitectureKai Yu, Jianfeng Chen, Yu-Yi Chu, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Nature Communications|April 28, 2025
Investigative needle core biopsies support multimodal deep-data generation in glioblastomaKenny K H Yu, Sreyashi Basu, Gerard Baquer, et al.
Medrxiv : the Preprint Server for Health Sciences|January 18, 2024
Investigative needle core biopsies for multi-omics in GlioblastomaKenny K H Yu, Sreyashi Basu, Gerard Baquer, et al.
Elife|December 6, 2017
The Human Cell AtlasAviv Regev, Sarah A Teichmann, Eric S Lander, et al.
Nature Communications|February 1, 2020
Comprehensive T cell repertoire characterization of non-small cell lung cancerAlexandre Reuben, Jiexin Zhang, Shin-Heng Chiou, et al.
Nature|October 22, 2025
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockadeAdam J Grippin, Christiano Marconi, Sage Copling, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Pageof 22

Showing results (201-210 of 216) with videos related to

Sort By:
Pageof 22
Cancer Discovery|December 2, 2025
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Cancer Discovery|May 13, 2026
A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune ArchitectureKai Yu, Jianfeng Chen, Yu-Yi Chu, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Nature Communications|April 28, 2025
Investigative needle core biopsies support multimodal deep-data generation in glioblastomaKenny K H Yu, Sreyashi Basu, Gerard Baquer, et al.
Medrxiv : the Preprint Server for Health Sciences|January 18, 2024
Investigative needle core biopsies for multi-omics in GlioblastomaKenny K H Yu, Sreyashi Basu, Gerard Baquer, et al.
Elife|December 6, 2017
The Human Cell AtlasAviv Regev, Sarah A Teichmann, Eric S Lander, et al.
Nature Communications|February 1, 2020
Comprehensive T cell repertoire characterization of non-small cell lung cancerAlexandre Reuben, Jiexin Zhang, Shin-Heng Chiou, et al.
Nature|October 22, 2025
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockadeAdam J Grippin, Christiano Marconi, Sage Copling, et al.
Nature Medicine|February 19, 2021
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trialTina Cascone, William N William, Annikka Weissferdt, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Pageof 22